ASE Test, Inc.'s Form 4 filing
Ainos, Inc. (AIMD) · filed Mar 12, 2025
- Accession no.
- 0000950103-25-003292
- Filed
- Mar 12, 2025
- Trade date
- Mar 10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| ASE Test, Inc.CIK 0002021793 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2025 | Common Stock, par value $0.01 | PPurchaseAcquired | +499,377 | –F2 | – | 499,377 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
As previously reported, the Issuer and ASE Test, Inc. entered into a Convertible Promissory Note Purchase Agreement, dated March 13, 2023 (the "2023 Agreement"), pursuant to which the Issuer issued convertible promissory notes to ASE Test, Inc. in the principal amount of $2,000,000 (the "Principal Amount") and six percent (6%) compounded interest of which was due on March 13, 2025. On March 10, 2025, the Issuer and ASE Test, Inc. entered into an amendment to the 2023 Agreement (the "2023 Agreement Amendment") to extend the maturity date to March 12, 2027 and change the conversion price from $7.50 per share to a conversion price equal to the lower of (a) $7.50 per share and (b) the higher of (x) the average closing price per share of the Issuer's common stock for the period of thirty (30) trading days prior to the day when the ASE Test, Inc. exercises the conversion right or (y) $4.50, subject to anti-dilutive adjustment as set forth in the 2023 Agreement Amendment.
Referenced by the price of 1 transaction in Table II.